Browsing by Author "Aydoğdu, İsmet"
Now showing 1 - 5 of 5
- Results Per Page
- Sort Options
Item Addition of thalidomide (t) to oral melphalan/prednisone (mp) in patients with multiple myeloma: Initial results of a randomized trial from the Turkish myeloma study group.(Amer Soc Hematology, 2009-11-20) Beksaç, Mehmet Sinan; Haznedar, Rauf; Fıratlı, Tülin Tuğlular; Özdoğu, Hakan; Aydoğdu, İsmet; Konuk, Nahide; Sucak, Gulşan Ayhan; Kaygusuz, Işık; Karakuş, Savaş; Kaya, Emin; Gülbaş, Zafer; Özet, Gülsüm; Göker, Hakan; Ündar, Levent; Ali, Rıdvan; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Anabilim Dalı.Item Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: Results of a randomized trial from the Turkish Myeloma Study Group(Wiley, 2011-01) Beksaç, Meral; Haznedar, Rauf; Tuğlular, Tulin Fıratlı; Özdoğu, Hakan; Aydoğdu, İsmet; Konuk, Nahide; Sucak, Gülşan; Kaygusuz, Işık; Karakuş, Sema; Kaya, Emin; Gülbaş, Zafer; Özet, Gülsüm; Göker, Hakan; Ündar, Levent; Ali, Rıdvan; Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı; 7201813027The combination of melphalan-prednisone-thalidomide (MPT) has been investigated in several clinical studies that differed significantly with regard to patient characteristics and treatment schedules. This prospective trial differs from previous melphalan-prednisone (MP) vs. MPT trials by treatment dosing, duration, routine anticoagulation, and permission for a crossover. Newly diagnosed patients with multiple myeloma (MM) (n = 122) aged greater than 55 yr, not eligible for transplantation were randomized to receive 8 cycles of M (9 mg/m2/d) and P (60 mg/m2/d) for 4 d every 6 wk (n = 62) or MP and thalidomide (100 mg/d) continuously (n = 60). Primary endpoint was treatment response and toxicities following 4 and 8 cycles of therapy. Secondary endpoints were disease-free (DFS) and overall survival (OS). Overall, MPT-treated patients were younger (median 69 yr vs. 72 yr; P = 0.016) and had a higher incidence of renal impairment (RI, 19% vs. 7%, respectively; P = 0.057). After 4 cycles of treatment (n = 115), there were more partial responses or better in the MPT arm than in the MP arm (57.9% vs. 37.5%; P = 0.030). However, DFS and OS were not significantly different between the arms after a median of 23 months follow-up (median OS 26.0 vs. 28.0 months, P = 0.655; DFS 21.0 vs. 14.0 months, P = 0.342, respectively). Crossover to MPT was required in 11 patients, 57% of whom responded to treatment. A higher rate of grade 3-4 infections was observed in the MPT arm compared with the MP arm (22.4% vs. 7.0%; P = 0.033). However, none of these infections were associated with febrile neutropenia. Death within the first 3 months was observed more frequently in the MP arm (n = 8, 14.0%) than in the MPT arm (n = 2, 3.4%; P = 0.053). Long-term discontinuation and dose reduction rates were also analyzed (MPT: 15.5% vs. MP: 5.3%; P = 0.072). Although patients treated with MPT were relatively younger and had more frequent RI, better responses and less early mortality were observed in all age groups despite more frequent discontinuation.Publication Efficacy and safety of ibrutinib therapy in patients with chronic lymphocytic leukemia: Retrospective analysis of real-life data(Galenos Yayıncılık, 2021-08-16) Tombak, Anıl; Tanrıkulu, Funda Pepedil; Durusoy, Salih Sertaç; Dinçyürek, Hüseyin Derya; Kaya, Emin; Ümit, Elif Gülsüm; Yavaşoğlu, İrfan; Mehtap, Özgür; Deveci, Burak; Özcan, Mehmet Ali; Terzi, Hatice; Okay, Müfide; Sayınalp, Nilgün; Yılmaz, Mehmet; Okan, Vahap; Kızıklı, Alperen; Özcan, Ömer; Çetin, Güven; Demircioğlu, Sinan; Aydoğdu, İsmet; Saydam, Güray; Davulcu, Eren Arslan; İlhan, Gül; Uçar, Mehmet Ali; Özet, Gülsüm; Akpınar, Seval; Turgut, Burhan; Berber, İlhami; Kurtoğlu, Erdal; Sönmez, Mehmet; Batur, Derya Selim; Yıldırım, Rahşan; Özkocamaz, Vildan; Güneş, Ahmet Kürşad; Sahip, Birsen; Ertop, Şehmus; Akay, Olga Meltem; Baştürk, Abdulkadir; Doğu, Mehmet Hilmi; Akdeniz, Aydan; Ünal, Ali; Seyhanlı, Ahmet; Gürkan, Emel; Çekdemir, Demet; Ferhanoğlu, Burhan; Özkocamaz, Vildan; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.; 0000-0003-0014-7398; DLC-4894-2022Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age +/- standard deviation: 64.6 +/- 10.3 years, 66.9% males) who had received at least one dose of ibrutinib were included in this retrospective multicenter, noninterventional hospital-registry study conducted at 33 centers across Turkey. Data on patient demographics, baseline characteristics, laboratory findings, and leukemia-cell cytogenetics were retrieved. Treatment response, survival outcome including overall survival (OS) and progression-free survival (PFS), and safety data were analyzed. Results: Overall, 36.7% of patients were categorized as Eastern Cooperative Oncology Group (ECOG) class 2-3, while 44.9% were in Rai stage 4. Fluorescence in situ hybridization revealed the presence of del(17p) in 39.8% of the patients. Patients received a median of 2.0 (range: 0-7) lines of pre-ibrutinib therapy. Median duration of therapy was 8.8 months (range: 0.4-58.0 months). The 1-year PFS and OS rates were 82.2% and 84.6%, respectively, while median PFS time was 30.0 (standard error, 95% confidence interval: 5.1, 20.0-40.0) months and median OS time was 37.9 (3.2, 31.5-44.2) months. Treatment response (complete or partial response), PFS time, and OS time were better with 0-2 lines versus 3-7 lines of prior therapy (p<0.001, p=0.001, and p<0.001, respectively), with ECOG class 0-1 versus class 2-3 (p=0.006, p=0.011, and p=0.001, respectively), and with Rai stage 0-2 versus 3-4 (p=0.002, p=0.001, and p=0.002, respectively). No significant difference was noted in treatment response rates or survival outcome with respect to the presence of comorbidity, bulky disease, or del(17p). While 176 adverse events (AEs) were reported in 74 (54.4%) patients, 46 of those 176 AEs were grade 3-4, including pneumonia (n=12), neutropenia (n=11), anemia (n=5), thrombocytopenia (n=5), and fever (n=5). Conclusion: This real-life analysis confirms the favorable efficacy and safety profile of long-term ibrutinib treatment while emphasizing the potential adverse impacts of poorer ECOG performance status, heavy treatment prior to ibrutinib, and advanced Rai stage on patient compliance, treatment response, and survival outcomes.Item Holotranskobalamin II’nin RIA ile ölçümünün megaloblastik anemi tanısındaki değeri ve diğer tanı parametreleri ile karşılaştırılması(Uludağ Üniversitesi, 2006-05-30) Şerefhanoğlu, Songül; Aydoğdu, İsmet; Kekili, Ersoy; Kuku, İrfanKobalamin eksikliğine bağlı megaloblastik aneminin değişken klinik belirti ve laboratuvar bulgularının olması tanıda zorluklara neden olmaktadır. Serum holotranskobalamin II (holoTC II) düzeyinin azalmasının kobalamin eksikliğinin tanısında erken bir markır olduğu belirtilmekle birlikte, klinik kullanıma uygun bir metot geliştirilmemiştir. Bu çalışmada, kobalamin eksikliğini belirlemede yeni bir ticari test olan holoTC II RIA (Radyoimmüno assay)’nın etkinliği ve diğer laboratuvar bulguları ile karşılaştırılması amaçlandı. Başvuru anında, 20 hastanın 14‘ünde (%70) anemi ve makrositoz, dokuzunda (%45) trombositopeni, yedisinde (%35) nötropeni, 10’unda (%50) serum kobalamin düzeyleri (<100 pg/mL) ve 19’unda (%95) holoTC II düzeyi düşük (<37 pmol/L) bulundu. On gün 1 mg/gün siyanokobalamin tedavisi sonrası hemoglobin, hematokrit, trombosit, serum kobalamin ve serum holoTC II değerlerinde tedavi öncesi ile mukayese edildiğinde istatistiksel olarak anlamlı derecede artış oldu (P<0.05). MCV, LDH ve indirekt bilirübin değerlerinde ise azalma oldu (P<0.05). Plazma holoTC II düzeyinin ölçümünün kobalamin eksikliğini belirlemede daha yüksek özgüllük ve duyarlılığa sahip olduğu bulundu.Item Retrospective and multicenter analysis of efficacy and safety of ruxolitinib in 176 Turkish patients with myelofibrosis: updated data(Pergamo-Elsevier Sciens Ltd, 2018-10) Soyer, Nur; Turgut, Mehmet; Haznedaroğlu, İbrahim; Yılmaz, Fergün; Aydoğdu, İsmet; Pir, Ali; Karakuş, Volkan; Özgür, Gökhan; Kis, C.; Ceran, Funda; İlhan, Gül; Özkan, Melda; Arslaner, M.; İnce, İdris; Ali, Rıdvan; Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Bilim Dalı.